Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Misses Estimates By $0.29 EPS

Inovio Pharmaceuticals (NASDAQ:INO) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.29), FiscalAI reports. The business had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $2.27 million.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Inovio received FDA accelerated approval for VOCERYQ, its first commercial product and the first FDA-approved plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). In the FDA’s analysis of 26 patients with at least three prior-year surgeries, 27% required no surgery in the 12 months after treatment; the company also cited durable responses and a generally favorable tolerability profile.
• Inovio is preparing a U.S. launch, with product availability expected about 60 days after approval and full field deployment targeted for Q1 2027. Management estimates at least 25,000 adult RRP patients in the U.S. and says its planned field team is designed to reach 90% of patient potential, though payer coverage and uptake estimates are based on company research.
• VOCERYQ’s accelerated approval requires a confirmatory study to verify clinical benefit, and continued approval may depend on its results. Inovio plans to submit a draft protocol by year-end and aims to agree on a final design with the FDA by mid-2027; the study is expected to include at least 50 adult and pediatric patients.
• After an equity offering that generated about $80.5 million in net proceeds, plus quarter-end cash and subsequent warrant exercises, Inovio expects to fund operations into late Q4 2027, excluding potential VOCERYQ revenue or future fundraising. The company reported Q3 operating expenses of $19.8 million, down from $21.2 million a year earlier; its $49.2 million net loss was primarily driven by a non-cash warrant fair-value adjustment.

Inovio Pharmaceuticals Price Performance

NASDAQ INO traded down $0.10 on Wednesday, hitting $1.35. 6,098,912 shares of the stock were exchanged, compared to its average volume of 4,851,283. The company’s 50-day moving average price is $1.18 and its two-hundred day moving average price is $1.27. The company has a market capitalization of $149.30 million, a price-to-earnings ratio of -1.49 and a beta of 1.71. Inovio Pharmaceuticals has a 52-week low of $0.56 and a 52-week high of $2.72.

Latest Inovio Pharmaceuticals News

Here’s some of the latest news about INO:

• Positive Sentiment: Management outlined a cash runway into late Q4 2027 and aims to submit a European filing for VOCERYQ by year-end 2026, offering visibility on near-term funding and regulatory milestones. Cash runway and VOCERYQ plans
• Negative Sentiment: Third-quarter results fell short of analyst expectations: INO reported a loss of $0.50 per share versus an expected $0.21 loss, while revenue was $0.30 million against a $2.27 million consensus. Q3 earnings results
• Negative Sentiment: Piper Sandler maintained its Overweight rating but cut its price target to $6 from $8, tempering its outlook despite the target remaining well above the share price cited in the report. Analyst rating and target

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on INO shares. Weiss Ratings cut Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating and set a $8.00 target price (up from $3.00) on shares of Inovio Pharmaceuticals in a research report on Friday. Wall Street Zen raised shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Piper Sandler reissued an “overweight” rating and issued a $6.00 price objective (down from $8.00) on shares of Inovio Pharmaceuticals in a report on Wednesday. Finally, Zacks Research lowered Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.33.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company’s platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio’s product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.